Table 1.
Demographics/characteristics of MONARCH sarilumab and adalimumab patient populations (base case analysis) and MOBILITY aggregate patient population (individual patient simulation)
| Demographics/characteristics | MONARCH | |
|---|---|---|
| Sarilumab SC 200 mg Q2W (n=184) | Adalimumab SC 40 mg Q2W/QW (n=185) | |
| Age, years, mean ± SD | 50.9±12.6 | 53.6±11.9 |
| Female, n (%) | 157 (85.3) | 150 (81.1) |
| Race, White–Caucasian, n (%) | 171 (92.9) | 164 (88.6) |
| Baseline HAQ-DI, mean ± SD | 1.6±0.6 | 1.6±0.6 |
| Baseline DAS28-ESR, mean ± SD | 6.8±0.8 | 6.8±0.8 |
| Duration of RA, years, mean ± SD | 8.1±8.1 | 6.6±7.8 |
| MOBILITY | ||
| Age, years, mean (range) ± SD | 50.6 (18–75)±11.6 | |
| Female, n (%) | 977 (81.6) | |
| Race, White–Caucasian, n (%) | 1,031 (86.1) | |
| Baseline HAQ-DI, mean (range) ± SD | 1.6 (0.0–3.0)±0.6 | |
| Duration of RA, years, mean (range) ± SD | 9.0 (0.3–44.7)±7.9 | |
Abbreviations: DAS28-ESR, Disease Activity Score 28-joint count erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; Q2W, every 2 weeks; QW, once weekly; RA, rheumatoid arthritis; SC, subcutaneous.